ppp and complement inhibition clinical trial commentary dr eric topol chairman and professor,...
TRANSCRIPT
PPP and Complement Inhibition
Clinical Trial Commentary
Dr Eric TopolChairman and Professor, Department of CardiologyDirector of the Joseph J Jacobs Center for Thrombosis and Vascular Biology at the Cleveland Clinic
Dr Robert CaliffProfessor of Cardiology Associate Vice Chancellor for Clinical Research at Duke University
Where we are nowPPP
Aspirin has been shown to be quite effective in secondary prevention, but there has been significant controversy about primary prevention
Physicians’ Health Study – stopped early, substantial reduction in non-fatal MI but an excess of hemorrhagic strokes (non-significant trend)
British study – did not show dramatic difference in primary prevention
Primary Prevention Project
Innovative approach: recruiting from daily practice
Open 22 factorial design in 4495 people with one or more major cardiovascular risk factor (hypertension, hypercholesterolemia, diabetes, obesity, family history of premature myocardial infarction, or old age) but no prior events or symptomatic angina
The PPP trial evaluated low-dose aspirin (100 mg/day) and vitamin E (300 mg/day)in a randomized, non-blinded study
PPP
ResultsPPP
Aspirin (n=2226)
No aspirin (n=2269)
Relative risk (95% CI)
Total cardiovascular events
6.3% 8.2% 0.77 (0.62–0.95)
Total mortality 2.8% 3.4% 0.81(0.58-1.13)
Cardiovascular mortality
0.8% 1.4% 0.56(0.31–0.99)
All stroke 0.7% 1.1% 0.67 (0.36–1.27)
Roncaglioni et al. Lancet 2001; 357:89-95
Design
“The ability to inexpensively randomize a large number of patients and get a result that’s this dramatic not only is an important finding for clinical practice, but also, I think, points the way to a system that we might use to more rapidly evaluate the effectiveness of simple interventions in primary care practice.”
Dr Robert CaliffProfessor of Cardiology Associate Vice Chancellor for Clinical Research at Duke University
PPP
Issues with the trial
Primary endpoint not significantCV death, non-fatal MI, non-fatal stroke
Relative risk = 0.71 (0.48–1.04)
Trial stopped earlyenrolled 4495 instead of the projected 7500 patients owing to the results of other trials that may not be germane
PPP
Choice of endpoint
Does total mortality trump a primary endpoint?
Should you pull out cardiovascular mortality?
Do partial studies weaken the implications of secondary endpoints?
PPP
Available dose
100-mg dose isn’t available in the US
Effectiveness of 80-mg dose seems to have been corroborated by several studies
Hypertension may be a contraindication for aspirin use (Hypertension Optimal Treatment trial)
PPP
Optimal dose
The optimal dose remains unresolved
Currently anywhere from 80 mg to 325 mg has been validated in one way or another
Correct dose of aspirin could be more effective for developing countries than the latest drug
A simple dose-comparison study is being proposed
PPP
Conclusions
CaliffPPP and HOT push him to recommend aspirin as primary prevention
TopolAspirin shows implications in many diseases other than cardiology
This is convincing, but would be more convincing if the trial had gone to completion
PPP
Pexelizumab (Alexion/Procter & Gamble):An anti-inflammatory C5 inhibitor monoclonal antibody fragment
914 patients scheduled for CABG surgery, or CABG plus valve replacement enrolled, randomized to:
• placebo • pexelizumab in a 2.0 mg/kg bolus• pexelizumab in a 2.0 mg/kg bolus followed
by a 24-hour infusion of pexelizumab at 0.05 mg/kg/h
Complement inhibition
Pexelizumab study
Results
30-day safety and efficacy follow-upResults only available from a press release
CABG-only group (n=796) Pexelizumab Placebo
Death 0.4% 1.9%
Non-Q-wave MI(CK-MB >100 ng/mL)
2.7% 8.0%
Death or MI (non-Q-wave or Q-wave)
7.8% 13.2%
Complement inhibition
Press release, Jan 26, 2001: Alexion Pharmaceuticals, Inc.
Perioperative MI
An area that has not been sufficiently studied
C5 inhibition may reduce perioperative MI
The mechanism is still unclear
Will it be verified?
What were the changing definitions of MI?
Complement inhibition
“I think it is important for cardiologists to be aware that there’s tremendous activity right now on the issue of preventing necrosis in the setting of bypass surgery, [because] the complexity of the operation and the morbidity is still quite high. This is despite clear improvements in the technology and the skill of the surgeons and the operating teams. But they’re just operating on very high-risk patients as we all know. So there’s a real niche for this type of therapy if it really works.”
Dr Robert Califf
Professor of Cardiology Associate Vice Chancellor for Clinical Research at Duke University
Complement inhibition
Preventing necrosis
Defining myocardial necrosis
Cardioplegia makes EKGs very unreliable because the majority of patients have some elevation of markers of necrosis
Where do you define the threshold?
How much necrosis do you need to prevent?
CARDINAL trials: direct angioplasty and thrombolysis, should add to the picture
There are multiple methods of inhibiting complement that are under investigation
Complement inhibition
Future of CABG
Bypass has been neglected for development of therapeutics and adjunctive medications
The dangers of periprocedural MI during CABG need to be examined, it isn’t revered enough
We may see a resurgence of CABG as technology allows for less severe patients to be operated on
Complement inhibition
Cognitive decline
Percentage of patients who suffered a declineof 20% or more in cognitive function frompre-CABG baseline
Complement inhibition
Time frame Patients suffering decline
Discharge 53%
6 weeks 36%
6 months 24%
5 years 42%
Newman M, et. al. N Engl J Med 2001; 344(6):395-402
Cognitive decline questions
Is this all related to bypass surgery, or is it associated with severe athereosclerosis?
How much is due to the bypass machine?
Does off-pump surgery prevent cognitivedecline?
Does complement inhibition help?
What genetic markers may indicate risk?
Complement inhibition